RGC
Live News • Jul 03
Regencell Bioscience Faces DOJ Investigation After May $20 Million Equity Raise and Heavy Losses Regencell Bioscience is under investigation by the U.S. Department of Justice following a subpoena related to trading activity in its shares, while also reporting no revenue, a net loss of $5.3 million and cash of about $2.4 million for the six months ended 31 December 2025, which has led the company to express doubt about its ability to continue as a going concern.
The company’s May 2026 registered direct offering raised $20 million at $20.30 per share, including a $19 million investment from a new institutional investor. The stock has since fallen sharply, leaving those offering participants significantly below their purchase price.
Regencell Bioscience shares last traded at $6.37, with the stock down 79.3% over the past 90 days, reflecting pressure around the offering, losses and the DOJ probe.
Taken together, the regulatory overhang, lack of revenue and limited cash leave Regencell Bioscience appearing highly dependent on future financing or a rapid shift in its operating profile, which may increase the risk of further dilution or financial strain for existing shareholders. New Risk • Jun 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Announcement • Jun 14
Pomerantz Law Firm Announces Filing of Class Action Against Regencell Bioscience Holdings Limited and Certain Officers Pomerantz LLP announced that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine ("TCM") for the treatment of attention-deficit/hyperactivity disorder ("ADHD") and autism spectrum disorder ("ASD")—two disorders generally considered incurable under current medical consensus. The Company asserts that while "[c]urrently available drugs and treatments in the markets for ADHD and ASD aim to suppress or alleviate symptoms," its "TCM formula aim[s] to treat the fundamental cause of neurocognitive disorders." (Emphasis added.)Regencell is a "controlled company" under the Nasdaq Capital Market's rules. Per Regencell's most recent annual report on Form 20-F, as of June 30, 2025, 88.8% of its shares were held by its directors and executive officers, with 88.6% of those shares owned by Defendant Yat-Gai Au ("Au")—the Company's founder, Chairman, and Chief Executive Officer. From the start of the Class Period through approximately mid-March 2025, Regencell's ordinary shares generally traded at less than 30 cents per share. However, beginning in early May 2025, the price for these shares suddenly skyrocketed. The meteoric rise in Regencell's ordinary share price has no evident connection to any public disclosures regarding its underlying business fundamentals. Regencell has twelve employees, no approved or salable products, no revenue, and has incurred operating losses since its formation. Further, notwithstanding its stated goal of curing medical disorders that are widely considered incurable, the Company's research and development ("R&D") costs were only $0.95 million and $1.07 million for the years ended June 30, 2025 and 2024, respectively. This stands in stark contrast with Regencell's own representations that "[a]verage [R&D] to marketplace cost for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion. 
